NASDAQ:NBRV - Nabriva Therapeutics Stock Price, Forecast & News

$1.45

-0.11 (-7.05 %)

(As of 01/23/2020 02:42 PM ET)

Add

Compare

Today's Range

$1.45

Now: $1.45▼

$1.55

50-Day Range

$1.21

MA: $1.49▼

$1.93

52-Week Range

$1.16

Now: $1.45▼

$3.27

Volume1.04 million shs

Average Volume1.34 million shs

Market Capitalization$1.37 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.31

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:NBRV

Previous Symbol

CUSIPN/A

CIK1641640

Webhttp://www.nabriva.com/

Phone353-1649-2000

Debt

Debt-to-Equity Ratio0.87

Current Ratio5.81

Quick Ratio5.79

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$9.66 million

Price / Sales141.93

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.10 per share

Price / Book14.50

Profitability

EPS (Most Recent Fiscal Year)($1.63)

Net Income$-114,780,000.00

Net Margins-910.45%

Return on Equity-171.36%

Return on Assets-93.30%

Miscellaneous

EmployeesN/A

Outstanding Shares945,450,000

Market Cap$1.37 billion

Next Earnings Date3/10/2020 (Estimated)

OptionableOptionable

Receive NBRV News and Ratings via Email

Sign-up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter.

(Ad)

A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

Nabriva Therapeutics (NASDAQ:NBRV) Frequently Asked Questions

What is Nabriva Therapeutics' stock symbol?

Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."

How were Nabriva Therapeutics' earnings last quarter?

Nabriva Therapeutics PLC - (NASDAQ:NBRV) posted its earnings results on Tuesday, November, 12th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.04. The biotechnology company earned $6.92 million during the quarter, compared to the consensus estimate of $1.23 million. Nabriva Therapeutics had a negative net margin of 910.45% and a negative return on equity of 171.36%. View Nabriva Therapeutics' Earnings History.

When is Nabriva Therapeutics' next earnings date?

Nabriva Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Nabriva Therapeutics.

What price target have analysts set for NBRV?

6 brokers have issued 1 year target prices for Nabriva Therapeutics' stock. Their forecasts range from $2.00 to $13.00. On average, they anticipate Nabriva Therapeutics' stock price to reach $7.50 in the next year. This suggests a possible upside of 417.2% from the stock's current price. View Analyst Price Targets for Nabriva Therapeutics.

What is the consensus analysts' recommendation for Nabriva Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nabriva Therapeutics.

What are Wall Street analysts saying about Nabriva Therapeutics stock?

Here are some recent quotes from research analysts about Nabriva Therapeutics stock:

1. According to Zacks Investment Research, "Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics' medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics' lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP). " (1/15/2020)
2. Northland Securities analysts commented, "We believe Xenleta is positioned to emerge as the 1st empiric monotherapy for treating CABP w/ potential global peak sales of $1B, supported by its significant clinical differentiation from existing therapies. Key Points Xenleta IV and Nabriva announced the FDA approval of Xenleta (lefamulin) IV and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP) in adults. This represents the first approval of a new class antibiotic in nearly 2 decades. Xenleta is a semi-synthetic pleuromutilin that works via a unique mechanism of action by inhibiting the synthesis of bacteria protein necessary of proliferation." (8/16/2019)
3. HC Wainwright analysts commented, "We employ a rNPV valuation model, driven by U.S. sales of: (1) lefamulin for CABP through 2028 (peak sales $460M); and (2) CONTEPO for cUTI through 2028 (peak sales $205M). We utilize a 15.0% discount rate for all cash flows, with zero terminal value after 2028, to arrive at our $7 price target (representing risk-adjusted per share values of about $6.50 for lefamulin and about $0.50 for CONTEPO). Risks to the attainment of our PT include failure to obtain FDA approval, unforeseen safety and/or tolerability issues, commercial sales trajectory meaningfully below then consensus expectations, and the dilution to current shareholders from additional equity offering(s)." (8/18/2019)

Has Nabriva Therapeutics been receiving favorable news coverage?

Headlines about NBRV stock have trended somewhat positive recently, InfoTrie reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nabriva Therapeutics earned a coverage optimism score of 1.8 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Nabriva Therapeutics.

Who are some of Nabriva Therapeutics' key competitors?

Some companies that are related to Nabriva Therapeutics include Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), Allakos (ALLK), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR), Blueprint Medicines (BPMC), FibroGen (FGEN), SAGE Therapeutics (SAGE), Mirati Therapeutics (MRTX), GW Pharmaceuticals PLC- (GWPH), Ultragenyx Pharmaceutical (RARE), Deciphera Pharmaceuticals (DCPH) and PTC Therapeutics (PTCT).

What other stocks do shareholders of Nabriva Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Zynerba Pharmaceuticals (ZYNE), Catalyst Pharmaceuticals (CPRX), Melinta Therapeutics (MLNT), Corbus Pharmaceuticals (CRBP), Dynavax Technologies (DVAX), Karyopharm Therapeutics (KPTI) and Tetraphase Pharmaceuticals (TTPH).

Who are Nabriva Therapeutics' key executives?

Nabriva Therapeutics' management team includes the folowing people:

Mr. Steven P. Gelone, Pres & COO (Age 51)
Dr. Colin Broom, Consultant & Director (Age 63)
Mr. Gary L. Sender, Chief Financial Officer (Age 57)
Mr. Theodore R. Schroeder, CEO & Director (Age 64)
Mr. Thomas Lembck, Chief Information Officer

Who are Nabriva Therapeutics' major shareholders?

Nabriva Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Clear Creek Financial Management LLC (0.01%) and Wedbush Securities Inc. (0.00%). Company insiders that own Nabriva Therapeutics stock include Charles A Rowland Jr, Colin Md Broom, Daniel D Burgess, Francesco Maria Lavino, Gary Sender, Jennifer Schranz, Robert Crotty, Stephen W Webster, Steven P Gelone and Theodore R Schroeder. View Institutional Ownership Trends for Nabriva Therapeutics.

Which major investors are selling Nabriva Therapeutics stock?

NBRV stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have sold Nabriva Therapeutics company stock in the last year include Colin Md Broom, Gary Sender and Steven P Gelone. View Insider Buying and Selling for Nabriva Therapeutics.

Which major investors are buying Nabriva Therapeutics stock?

NBRV stock was purchased by a variety of institutional investors in the last quarter, including Clear Creek Financial Management LLC. Company insiders that have bought Nabriva Therapeutics stock in the last two years include Charles A Rowland Jr, Colin Md Broom, Daniel D Burgess, Francesco Maria Lavino, Gary Sender, Jennifer Schranz, Robert Crotty, Stephen W Webster and Theodore R Schroeder. View Insider Buying and Selling for Nabriva Therapeutics.

How do I buy shares of Nabriva Therapeutics?

Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Nabriva Therapeutics' stock price today?

One share of NBRV stock can currently be purchased for approximately $1.45.

How big of a company is Nabriva Therapeutics?

Nabriva Therapeutics has a market capitalization of $1.37 billion and generates $9.66 million in revenue each year. The biotechnology company earns $-114,780,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. View Additional Information About Nabriva Therapeutics.

What is Nabriva Therapeutics' official website?

The official website for Nabriva Therapeutics is http://www.nabriva.com/.

How can I contact Nabriva Therapeutics?

Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN 1 L2, 19406. The biotechnology company can be reached via phone at 353-1649-2000 or via email at [email protected]

MarketBeat Community Rating for Nabriva Therapeutics (NASDAQ NBRV)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		348 (Vote Outperform)
Underperform Votes:		274 (Vote Underperform)
Total Votes:		622

MarketBeat's community ratings are surveys of what our community members think about Nabriva Therapeutics and other stocks. Vote "Outperform" if you believe NBRV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBRV will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 1/23/2020 by MarketBeat.com Staff

Featured Article: How are dividend achievers different from dividend aristocrats?

Your Ultimate Investing Toolkit

Just $1.00 for your first month.